Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Songling Xuemaikang plus antihypertensive therapy for essential hypertension with dyslipidemia in young and middle-aged adults
ChiCTR2400086235Phase 4Not yet recruiting
- Sponsor
- Shaanxi Provincial Transportation Hospital
- Start
- Jun 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of songling xuemaikang in essential hypertension and dyslipidemia (2 arms), sponsored by Shaanxi Provincial Transportation Hospital. Primary endpoint: Compliance rate of blood pressure-lipid composite indicators. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
songling xuemaikang
03
Conditions
essential hypertensiondyslipidemia
Beyond the preview
Go deeper on ChiCTR2400086235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086235.